SymbolAZN
NameASTRAZENECA PLC
SectorHEALTH CARE
RegionEurope
Industry-
Address10179 United States NY 383 Madison Avenue Floor 11
Telephone+44 20 3749 5000
Fax
Email
Websitehttp://www.astrazeneca.com
IncorporationGB
Incorporated On
Employees
Fiscal Year12/31
Public Since
ExchangesOTC;NASDAQ;NYSE
Auditor
Audit StatusAUDITED
Reporting StatusU.S. Reporting: SEC Reporting
CIK0000901832
Description

AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive open and collaborative. This approach runs through all that we do. We focus on three main therapy areas Oncology Cardiovascular & Metabolic Disease CVMD and Respiratory and we are also selectively active in the areas of autoimmunity neuroscience and infection.

Additional info from NASDAQ:
AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive open and collaborative. This approach runs through all that we do. We focus on three main therapy areas Oncology Cardiovascular & Metabolic Disease CVMD and Respiratory and we are also selectively active in the areas of autoimmunity neuroscience and infection.

2026-04-27 11:00

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Read more
2026-04-27 10:29

ASTRAZENECA PLC (AZN) Files Form 6-K

Read more
2026-04-23 10:10

ASTRAZENECA PLC (AZN) Files Form 6-K

Read more
2026-04-21 10:19

ASTRAZENECA PLC (AZN) Files Form 6-K

Read more
2026-04-20 11:03

ASTRAZENECA PLC (AZN) Files Form 6-K

Read more
2026-04-20 11:00

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Read more
2026-04-09 17:01

ASTRAZENECA PLC (AZN) Files Form 6-K

Read more
2026-04-08 15:21

New Form 25-NSE - ASTRAZENECA PLC <b>Filed:</b> 2026-04-08 <b>AccNo:</b> 0000876661-26-000343 <b>Size:</b> 3 KB

Read more
2026-04-02 13:27

ASTRAZENECA PLC (AZN) Files Form 6-K

Read more
2026-04-02 11:00

IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

Read more